Infectious disease marker testing, ABO and RhD typing and clonogenic assays must be done in accordance with the HTA guide to quality and safety assurance for tissues and cells for patient treatments -updated on January 2021, and the SaBTO guidance.
Additional information and guidance available with FACT-JACIE, WMDA and NetCord-FACT standards.
The minimum current requirements for mandatory and additional microbiology testing (serology and/or NAT) are described in Chapter 9.
Annex 7 indicates the requirements for the timing of testing for each type of HPC.